Erlotinib, Vandetanib, Lapatinib, and Axitinib are FDA-approved drugs that affect protein tyrosine kinases, inhibit EGFR and VEGFR, and are used to treat cancers such as lung cancer, breast cancer, thyroid cancer, and melanoma50. This evidence concerns the gene EGFR and lung carcinoma.